Last reviewed · How we verify
naproxcinod 750 bid
At a glance
| Generic name | naproxcinod 750 bid |
|---|---|
| Sponsor | NicOx |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics Study: Determination of Naproxcinod and Its Metabolites After Oral Administration in Male (PHASE1)
- A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure (PHASE1)
- Analgesic Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee (PHASE3)
- Effect of Repeated Dosing of Naproxcinod on Renal Hemodynamic and on Sodium Balance in Healthy Volunteers Before and After a Single Dose of Furosemide (PHASE1)
- To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension (PHASE1)
- Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee (PHASE3)
- A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects (PHASE1)
- Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- naproxcinod 750 bid CI brief — competitive landscape report
- naproxcinod 750 bid updates RSS · CI watch RSS
- NicOx portfolio CI